

**Table 1. Clinical and pathologic features of patients in Cohort 1 (Stage II-III CRC)**

		<b>N (%)</b>
<b>Gender</b>	Male	124 (57%)
	Female	94 (43%)
<b>Age</b>	≤ 65 years	82 (38%)
	> 65 years	136 (62%)
<b>Adjuvant CT</b>	Yes	88 (43%)
	No	115 (57%)
<b>Adjuvant CT regimen</b>	Mayo Clinic	74 (84%)
	De Gramont	5 (6%)
	Tomudex	3 (3%)
	FOLFOX-4	1 (1.5 %)
	UFT+LV	4 (4%)
	Unknown	1(1.5%)
<b>Tumor location</b>	Right colon	56 (26%)
	Other location	162 (74%)
<b>Bowel Obstruction</b>	Yes	45 (21%)
	No	173 (79%)
<b>Bowel Perforation</b>	Yes	16 (7%)
	No	202 (93%)
<b>T</b>	pT1-T3	191 (88%)
	pT4	25 (12%)
<b>N</b>	pN0	144 (66%)
	pN+	73 (34%)
<b>Tumor grade</b>	I	98 (45%)
	II-III	110 (55%)
<b>Stage</b>	II	144 (66%)
	III	73 (33,6)
<b>ECOG</b>	0	157 (85%)
	1	18 (10%)
	≥ 2	10 (5%)
<b>Relapse</b>	Yes	51 (25%)
	No	163 (75%)

T: tumor; N: node; ECOG: performance status per Eastern Cooperative Group criteria; CT: chemotherapy.

**Table 2. Clinical and pathologic features of patients in Cohort 2 (stage IV CRC)**

	<b>Non-responders (N=40)</b>	<b>Responders (N=46)</b>
Age (years)		
Median [range]	66 [61.0-71.0]	63.5 [55.0-70.5]
Gender		
Male	22 (55.0%)	31 (67.4%)
Female	18 (45.0%)	15 (32.6%)
Primary tumour location		
Ascending colon	13 (32.5%)	6 (13.0%)
Transverse colon	1 (2.5%)	2 (4.3%)
Descending colon	-	4 (8.7%)
Sigmoid colon	16 (40.0%)	20 (43.5%)
Rectosigmoid colon	-	1 (2.2%)
Rectum	10 (25.0%)	13 (28.3%)
Histology of primary tumour		
Adenocarcinoma NOS	37 (92.5%)	45 (97.8%)
Mucinous adenocarcinoma	3 (7.5%)	1 (2.2%)
Localisation of Metastasis		
Hepatic	26 (65.0%)	31 (67.4%)
Lung	9 (22.5%)	13 (28.3%)
Peritoneal	4 (10.0%)	12 (26.1%)
Other	13 (32.5%)	11 (23.9%)
Chemotherapy regimen		
Ox/FP regimens	31 (77.5%)	36 (78.3%)
Ir/FP regimens	6 (15.0%)	6 (13.0%)
Ox/Ir/FP	1 (2.5%)	3 (6.5%)
FP monotherapy	2 (5.0%)	1 (2.2%)
PFS (months)		
Median [range]	8.6 [4.2-12.9]	12.5 [10.1-21.3]
OS (months)		
Median [range]	15.6 [9.2-26.8]	28.4 [18.2-35.0]

Ox: oxaliplatin; FP: fluoropyrimidine; Ir: Irinotecan; NOS: not otherwise specified; PFS: progression-free survival; OS: overall survival.